Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted) (2021 - 2026)
Nurix Therapeutics (NRIX) reported EPS (Weighted Average and Diluted) of -$0.79 for Q1 2026, down 17.91% year-over-year from -$0.96 in Q1 2025, and up 4.82% quarter-over-quarter from -$0.83 in Q4 2025.
Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.79 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.79, down 17.91% year-over-year; the trailing twelve-month figure through Feb 2026 was -$3.17 (down 13.21% YoY), and the FY2025 annual result was -$3.05, down 5.9% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.79 in Q1 2026 per NRIX's latest filing, from -$0.83 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.45 in Q2 2023 and troughed at -$1.03 in Q3 2025.
- A 5-year average of -$0.77 and a median of -$0.76 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) sank 68.33% in 2022, then jumped 55.45% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.86 in 2022, then gained by 10.47% to -$0.77 in 2023, then gained by 2.6% to -$0.75 in 2024, then declined by 10.67% to -$0.83 in 2025, then grew by 4.82% to -$0.79 in 2026.
- Business Quant data shows NRIX's EPS (Weighted Average and Diluted) at -$0.79 in Q1 2026, -$0.83 in Q4 2025, and -$1.03 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -0.79 |
| Nov 30, 2025 | -0.83 |
| Aug 31, 2025 | -1.03 |
| May 31, 2025 | -0.52 |
| Feb 28, 2025 | -0.67 |
| Nov 30, 2024 | -0.75 |
| Aug 31, 2024 | -0.67 |
| May 31, 2024 | -0.71 |
| Feb 29, 2024 | -0.76 |
| Nov 30, 2023 | -0.77 |
| Aug 31, 2023 | -0.68 |
| May 31, 2023 | -0.45 |
| Feb 28, 2023 | -0.75 |
| Nov 30, 2022 | -0.86 |
| Aug 31, 2022 | -0.90 |
| May 31, 2022 | -1.01 |
| Feb 28, 2022 | -0.95 |
| Nov 30, 2021 | -0.85 |
| Aug 31, 2021 | -0.65 |
| May 31, 2021 | -0.60 |